Table 1

Patient characteristics

Patient characteristicsNormal practice
n (%)
New Medicine Service
n (%)
Total n (%)253 (100.0)251 (100.0)
Antiplatelet/anticoagulant (n=43, 8.5%)19 (7.5)24 (9.6)
Asthma/COPD (n=117, 23.2%)58 (22.9)59 (23.5)
Hypertension (n=249, 49.4%)128 (50.6)121 (48.2)
Type 2 diabetes (n=95, 18.8%)48 (19.0)47 (18.7)
Female (n=260, 51.6%)135 (53.4)125 (49.8)
Male (n=244, 48.4%)118 (46.6)126 (50.2)
Total cohort age (years) (n: mean (SD))253: 59.3 (15.0)251: 59.5 (15.3)
Female age (years) (n: mean (SD))135: 58.7 (15.4)125: 56.8 (16.0)
Male age (years) (n: mean (SD))118: 60.0 (14.6)126: 62.2 (14.1)
Number of NMS eligible new medicine(s) at study entry, n (%)Total NMS medicines: 257Total NMS medicines: 262
 1249 (98.4)241 (96.0)
 24 (1.6)9 (3.6)
 30 (0.0)1 (0.4)
Mean (SD) number of other medicines3.6 (3.4)3.5 (3.4)
Economic deprivation based on IMD score* (mean (SD))
 Pharmacy study sites30.7 (14.0)31.1 (13.6)
 Study patients25.0 (15.0)24.2 (15.3)
Location of pharmacy study site, n (%)
 Derbyshire (9 pharmacies)46 (18.2)55 (21.9)
 South Yorkshire (5 pharmacies)35 (13.8)31 (12.4)
 Leicestershire (8 pharmacies)15 (5.9)10 (4.0)
 Nottinghamshire (14 pharmacies)117 (46.2)114 (45.4)
 Greater London (10 pharmacies)40 (15.8)41 (16.3)
Pharmacy ownership†, n (%)
 Independent65 (25.7)56 (22.3)
 Large multiple63 (24.9)68 (29.1)
 Small multiple122 (48.2)123 (49.0)
 Supermarket3 (1.2)4 (1.6)
  • *Index of Multiple Deprivation (IMD) score: score is proportional to level of deprivation. A higher score indicates an area of higher deprivation (English deprivation scores range from 0.5 to 87.8).

  • †Large multiple and supermarket: the 10 largest pharmacy entities in England. Small multiple: pharmacies with six or more branches. Independent: pharmacies with one to five branches.

  • COPD, chronic obstructive pulmonary disease; NMS, New Medicine Service.